

MS4A1 & CD3E

Research Grade Glofitamab

Catalog No.	DHC90714A DHC90714B	Quantity:	100 µg 1.0 mg
Alternate Names:	Bispecific, CD20-TCB (2:1), RG-6026, CAS: 2229047-91-8		
Description:	Research Grade Glofitamab is a bispecific humanized monoclonal antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab is an investigational, T-cell bispecific antibody with a distinctive design that features 2 Fab arms for binding CD20 on B cells, along with 1 Fab arm for binding CD3 on T cells. The CD3 binding arm is fused directly to one of the CD20-binding arms in a head-to-tail fashion via a short flexible linker.		
UniProt ID (target):	P11836 & P07766		
Specificity:	Human B-lymphocyte antigen CD20 & T-cell surface glycoprotein CD3 epsilon chain		
Source:	XtenCHO cell line		
Isotype:	Human IgG1-kappa-lambda		
INN:	Glofitamab		
Concentration:	1.0 mg/ml, lot specific		
Formulation:	0.01M PBS, pH 7.4.		
Purity:	> 95% as determined by SDS-PAGE		
Purification:	Protein A/G affinity chromatography		
Endotoxin:	≤ 0.01 EU/µg by LAL analysis		
Storage & Stability:	Recommended storage, undiluted at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. Avoid freeze/thaw cycles.		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

